A phase II study of Velcade (Rm) (bortezomib) in patients stage IIIB or IV non-small cell lung cancer (NSCLC) who have not received prior chemotherapy
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2013
At a glance
- Drugs Bortezomib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Mar 2008 Status changed from recruiting to discontinued.
- 16 Oct 2006 New trial record.